Oramed Pharmaceuticals Inc. (ORMP) — SEC Filings
Oramed Pharmaceuticals Inc. (ORMP) — 42 SEC filings. Latest: 8-K (Dec 31, 2025). Includes 30 8-K, 6 10-Q, 2 10-K.
View Oramed Pharmaceuticals Inc. on SEC EDGAR
Overview
Oramed Pharmaceuticals Inc. (ORMP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: On December 31, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in corporate governance and potential adjustments to how key personnel are compensated.
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 1 bullish, 39 neutral, 2 mixed. The dominant filing sentiment for Oramed Pharmaceuticals Inc. is neutral.
Filing Type Overview
Oramed Pharmaceuticals Inc. (ORMP) has filed 30 8-K, 6 10-Q, 1 10-K/A, 2 10-K, 1 SC 13G, 1 DEF 14A, 1 SC 13D with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of ORMP's 39 recent filings, 2 were flagged as high-risk, 26 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2.000M |
| Net Income | $54.007M |
| EPS | $1.30 |
| Debt-to-Equity | 0.06 |
| Cash Position | $52.179M |
| Operating Margin | -219.65% |
| Total Assets | $220.493M |
| Total Debt | $12.044M |
Key Executives
- Dr. Miriam Kidron
- Mr. Jonathan Kolber
- Dr. Michal Y. Yarkoni
- Mr. Boaz Weiss
- Ms. Tamar Y. Yarkoni
- Mr. David Yarkoni
- Nadav Kidron
Industry Context
The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and stringent regulatory approvals. Companies often rely on strategic partnerships and investments to diversify their pipelines and mitigate risks. The current landscape sees increased focus on specialized therapies and innovative drug delivery systems.
Top Tags
material-agreement (10) · filing (7) · corporate-action (5) · pharmaceuticals (5) · corporate-governance (4) · 10-Q (4) · acquisition (4) · merger (4) · 8-k (3) · Pharmaceuticals (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-35813 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 98-0376008 | Company's tax identification number. |
| Net Income | $54.007M | Swung from a $8.904M loss in 2024 to a profit for the nine months ended September 30, 2025. |
| Financial Income, Net | $74.278M | Primary driver of net income, up from $3.902M in the prior year. |
| Revenues | $2.000M | Generated for the nine months ended September 30, 2025, compared to zero in 2024. |
| Total Assets | $220.493M | Increased from $155.278M at December 31, 2024, reflecting new investments. |
| Investment in Alpha Tau Medical Ltd. | $36.900M | Acquisition of approximately 17% stake in April 2025. |
| Research and Development Expenses | $4.393M | Decreased by 9.66% from $4.863M in the prior year. |
| General and Administrative Expenses | $5.036M | Increased by 16.49% from $4.323M in the prior year. |
| Shares Outstanding | 39,802,455 | As of November 12, 2025. |
| Basic Income Per Share | $1.30 | For the nine months ended September 30, 2025, up from $(0.22) in 2024. |
| Ownership in Oravax Medical Inc. | 63% | Company holds 63% of Oravax's issued and outstanding share capital. |
| Net Income (Q2 2025) | $13,260 | Increased from $9,204 thousand in Q2 2024 |
| Net Income (Six months ended June 30, 2025) | $5,618 | Decreased from $10,738 thousand in the same period of 2024 |
| Revenues (Six months ended June 30, 2025) | $2,000 | No revenue reported in the prior-year period |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Oramed Pharmaceuticals Inc. (ORMP)?
Oramed Pharmaceuticals Inc. has 42 recent SEC filings from Jan 2024 to Dec 2025, including 30 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ORMP filings?
Across 42 filings, the sentiment breakdown is: 1 bullish, 39 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Oramed Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Oramed Pharmaceuticals Inc. (ORMP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Oramed Pharmaceuticals Inc.?
Key financial highlights from Oramed Pharmaceuticals Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ORMP?
The investment thesis for ORMP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Oramed Pharmaceuticals Inc.?
Key executives identified across Oramed Pharmaceuticals Inc.'s filings include Dr. Miriam Kidron, Mr. Jonathan Kolber, Dr. Michal Y. Yarkoni, Mr. Boaz Weiss, Ms. Tamar Y. Yarkoni and 2 others.
What are the main risk factors for Oramed Pharmaceuticals Inc. stock?
Of ORMP's 39 assessed filings, 2 were flagged high-risk, 26 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Oramed Pharmaceuticals Inc.?
Forward guidance and predictions for Oramed Pharmaceuticals Inc. are extracted from SEC filings as they are enriched.